AVEO PHARMACEUTICALS INC (AVEO) Stock Overview
USA - NASDAQ:AVEO - US0535883070 - Common Stock
AVEO Key Statistics, Chart & Performance
The current stock price of AVEO is 15 USD. In the past month the price increased by 0.6%. In the past year, price increased by 338.6%.
AVEO Latest News, Press Relases and Analysis
AVEO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About AVEO
Company Profile
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. The company is headquartered in Boston, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2010-03-12. The firm is focused on delivering medicines for patients with cancer. The Company’s commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The firm markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. The company also develops FOTIVDA in immuno-oncology combinations in refractory RCC and other indications and has several other investigational programs in clinical development. The Company’s pipeline of product candidates includes ficlatuzumab, AV-380, AV-203 and AV-353. Its ficlatuzumab is a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF).
Company Info
AVEO PHARMACEUTICALS INC
30 Winter Street
Boston MASSACHUSETTS 02108 US
CEO: Michael Bailey
Employees: 114
Phone: 18574000101.0
AVEO PHARMACEUTICALS INC / AVEO FAQ
What does AVEO do?
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. The company is headquartered in Boston, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2010-03-12. The firm is focused on delivering medicines for patients with cancer. The Company’s commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The firm markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. The company also develops FOTIVDA in immuno-oncology combinations in refractory RCC and other indications and has several other investigational programs in clinical development. The Company’s pipeline of product candidates includes ficlatuzumab, AV-380, AV-203 and AV-353. Its ficlatuzumab is a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF).
Can you provide the latest stock price for AVEO PHARMACEUTICALS INC?
The current stock price of AVEO is 15 USD.
Does AVEO PHARMACEUTICALS INC pay dividends?
AVEO does not pay a dividend.
How is the ChartMill rating for AVEO PHARMACEUTICALS INC?
AVEO has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is AVEO PHARMACEUTICALS INC (AVEO) stock traded?
AVEO stock is listed on the Nasdaq exchange.
What do analysts say about AVEO PHARMACEUTICALS INC (AVEO) stock?
10 analysts have analysed AVEO and the average price target is 15.3 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 15.
What is the expected growth for AVEO stock?
The Revenue of AVEO PHARMACEUTICALS INC (AVEO) is expected to grow by 163.12% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
AVEO Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to AVEO. When comparing the yearly performance of all stocks, AVEO is one of the better performing stocks in the market, outperforming 99.55% of all stocks.
AVEO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVEO. AVEO has a bad profitability rating. Also its financial health evaluation is rather negative.
AVEO Financial Highlights
Over the last trailing twelve months AVEO reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS increased by 56.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.94 |
AVEO Forecast & Estimates
10 analysts have analysed AVEO and the average price target is 15.3 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 15.
For the next year, analysts expect an EPS growth of 59.87% and a revenue growth 163.12% for AVEO